STOCK TITAN

[144] Taysha Gene Therapies, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

An insider of TSHA has filed a notice of proposed sale under Rule 144 to sell up to 100,846 shares of common stock through broker Maxim Group LLC around 01/23/2026 on Nasdaq.

The shares were acquired on the same date via a vested RSU award from the issuer, with consideration described as the reporting person's continued service as an employee. The notice lists an aggregate market value of $513,306.14 for the planned sale and states that 273,919,373 common shares were outstanding.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the TSHA Rule 144 filing describe?

It describes a planned sale of 100,846 TSHA common shares by an insider under Rule 144, to be executed through broker Maxim Group LLC on Nasdaq.

How many TSHA shares are planned to be sold and at what value?

The filing lists 100,846 common shares to be sold, with an aggregate market value of $513,306.14 at the time of the notice.

How and when did the TSHA insider acquire the 100,846 shares?

The shares were acquired on 01/23/2026 via a restricted stock unit (RSU) award from the issuer, described as a vested grant settled in stock.

What was the consideration for the RSU award in the TSHA filing?

The consideration for the RSU award is stated as the reporting person’s continued service as an employee of the issuer.

How many TSHA shares were outstanding according to the filing?

The notice states that there were 273,919,373 TSHA common shares outstanding at the time referenced.

On which exchange and through which broker may the TSHA shares be sold?

The planned sale is listed for the Nasdaq exchange, through broker Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022.
Taysha Gene Therapies, Inc.

NASDAQ:TSHA

TSHA Rankings

TSHA Latest News

TSHA Latest SEC Filings

TSHA Stock Data

1.39B
242.89M
11.15%
94.76%
14.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
DALLAS